Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

NeuroPace RNS System

An implantable neurostimulator for adjunctive therapy in adults with partial-onset seizures refractory to at least 2 antiepileptic medications.  

Lariat Suture Delivery Device

A percutaneously delivered suturing device for closure of the left atrial appendage intended for stroke prevention in patients with atrial fibrillation, especially those who cannot tolerate anticoagulant medications. 

Ibrance (Palbociclib)

An oral cyclin-dependent kinase 4 and 5 inhibitor to treat metastatic breast cancer, in combination with letrozole.

APPY1 Screening Test

A blood-based test that uses multiple biomarkers and a proprietary algorithm; intended for adjunctive use in the emergency setting for screening or triage of children and adolescents with suspected acute appendicitis.

Rytary (IPX066)

An extended-release capsule formulation of carbidopa/levodopa for the treatment of Parkinson’s disease.

CardioMEMS HF System

A permanently implantable sensor that wirelessly monitors pulmonary artery pressures and other hemodynamic parameters, and transmits data to clinicians managing patients with New York Heart Association Class III heart failure.